Partners launch new regenerative medicine company
Kidswell Bio and Treehill Partners have announced the creation of a new US based regenerative medicine company, Kidswell USA.
The companies say Kidswell USA will be formed for the purpose of accelerating the development of Kidswell’s cell therapy pipeline, currently targeting cerebral palsy (CP) as a lead indication.
It is estimated that the prevalence of CP in the US is one in 345 children. The NIH reports that approximately 8,000 to 12,000 infants born each year develop the condition. Currently, only symptomatic treatments are available for CP patients.
Kidswell will develop stem cells derived from human exfoliated deciduous teeth (SHED) as a regenerative therapy platform. The lead programme SQ-SHED has already shown strong initial signals of clinical efficacy in CP.
Kidswell and Treehill have selected Thermo Fisher Scientific as their preferred development service partner.
“Kidswell is seeking to develop its most innovative therapies for the US market, and to accelerate this process we have selected partners that will enable us to jointly create a clinical development roadmap. This roadmap will provide the best opportunities for success with the most financially efficient routes, and provide therapies that are commercially viable for the market. This will result in new therapies for underserved indications where patients have few alternative therapeutic options,” said Shinya Kurebayashi, President & CEO, Kidswell Bio Corporation.
“Too many promising therapies fail unnecessarily in clinical development or never reach patients due to inefficient development pathways and poor capital discipline,” said Ali Pashazadeh, CEO and Founder of Treehill Partners. “Partnering with Kidswell will speed up the advancement of its cell therapy for paediatric cerebral palsy, a programme with meaningful clinical potential and significant unmet need.”
